BORDEAUX CLINICAL RESEARCH NETWORK (BCRN) fulfills increasing CRO and industry sponsor requirements to boost patient inclusion rates and speed up Phase I-to-Phase IV tests, while ensuring compliance with all applicable quality standards. BCRN is the first public/private R&D accelerator for the healthcare industry to be set up in France.
BORDEAUX CLINICAL RESEARCH NETWORK is headquartered in Talence, near Bordeaux, in south-western France. Set up on 1 February 2011, it is a service platform dedicated to clinical trials run by the healthcare industry.
BORDEAUX CLINICAL RESEARCH NETWORK is the first entity of its kind in France, and without equivalent in other European countries; it constitutes a unique public/private partnership and a powerful accelerator in research and development for the healthcare sector.
Within a highly demanding and competitive R&D environment, regions seeking to increase their attractiveness from an economic and scientific standpoint will want to provide a framework for structured development that may benefit the public- and private-sector players that make up the industry-sponsored clinical trial outsourcing chain; this rationale lies behind the creation of BORDEAUX CLINICAL RESEARCH NETWORK.
On the basis of an agreement entered into by industry players, hospitals and universities, BORDEAUX CLINICAL RESEARCH NETWORK has set clear goals to this project.
Firstly, BORDEAUX CLINICAL RESEARCH NETWORK aims to achieve higher patient inclusion rates in the operation of high-potential industry-sponsored clinical trials.
A second key aim is to become a ‘one-stop shop’ for industry sponsors and investigation sites, while assisting in building contacts across the sector; this will allow for better streamlining of procedures, thus increasing efficiency and reducing lead times on trials.
Thirdly, BORDEAUX CLINICAL RESEARCH NETWORK aims to optimize patient enrollment through the implementation of a practitioners’ network, in close collaboration with hospital investigation sites.
As a Site Management Organization (SMO), BORDEAUX CLINICAL RESEARCH NETWORK offers a range of services in three critical areas, as follows.
First of all, BCRN provides assistance in the setting-up of clinical trials, covering protocol analysis and investigator selection; financial proposals; a single contract for all parties involved; and finally, optional service proposals relating to the analysis of logistical requirements.
BCRN is also in a position to reinforce investigation/site management capabilities through the sourcing, allocation and management of medical and paramedical staff; through the setting-up of practitioner partnerships in order to allow for the enrollment, inclusion and monitoring of patients; and finally, through the provision of administrative and logistical support to practitioner networks.
BCRN also lends support to innovative projects, encompassing the analysis of requirements; the drafting of protocols; the identification of means of investigation; and, finally, assistance in fulfilling regulatory requirements as well as assistance in project implementation and management.
BCRN has been made possible thanks to the combination of the assets and skills of its four founding entities—BORDEAUX UNIVERSITY HOSPITAL, the BERGONIÉ INSTITUTE (i.e. the Regional Cancer Centre), BORDEAUX SEGALEN UNIVERSITY, and the INDUSTRIAL RESEARCH SUPPORT COMPANY (SARI). Founded on the initiative of the Bordeaux Chamber of Commerce and Industry, SARI brings together 12 local SMEs drawn from the relevant sectors, i.e. pharmaceuticals, medical devices and nutrition.
For industry sponsors and CROs, both in France and worldwide, BCRN is the ideal solution for easy access to a significant number of potential patients over a wide range of therapeutic fields.
About the BORDEAUX CLINICAL RESEARCH NETWORK (BCRN)
BCRN constitutes the first public/private R&D accelerator for the healthcare industry of its kind in France.
For further information, please contact Ms Marie-Odile Vergez on + 33 6 89 86 53 09 (telephone) or [email protected] (e-mail).
For further information, please contact :
Quote ref. : FTPB3611
Ms Mary-Ann WILLIAMS - Press Officer
UBIFRANCE Press Office in London
Tel: +44 (0) 207 024 3640
View other press releases at :